Armand P, et al. - Researchers reported the safety and efficacy outcomes after an extended follow-up of the multicohort single-arm phase II CheckMate 205 trial of nivolumab for classic Hodgkin lymphoma (cHL), a study wherein nivolumab, a programmed death-1 checkpoint inhibitor, demonstrated efficacy in relapsed/refractory cHL after autologous hematopoietic cell transplantation (auto-HCT) in initial analyses of one of three cohorts. The primary end point was objective response rate per independent radiology review committee. Nivolumab was shown to elicit frequent and durable responses after extended follow-up. Lipase increases (5%), neutropenia (3%), and ALT increases (3%) were reported as the most common grade 3 to 4 drug-related adverse events. Across a broad spectrum of patients with relapsed/refractory cHL, nivolumab seemed to be related to a favorable safety profile and long-term benefits.